Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma

Br J Haematol. 2019 Jan;184(2):298-302. doi: 10.1111/bjh.15079. Epub 2018 Jan 30.
No abstract available

Keywords: BCL2; PI3K/AKT; mantle cell lymphoma.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / mortality*
  • Male
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperidines
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Survival Rate
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • ibrutinib
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Adenine
  • venetoclax